Share Name Share Symbol Market Type Share ISIN Share Description
Avacta LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10p -0.41% 24.20p 23.60p 24.80p 24.30p 24.20p 24.30p 23,482 15:42:43
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 2.8 -10.4 -13.5 - 18.15

Avacta Share Discussion Threads

Showing 3801 to 3825 of 3825 messages
Chat Pages: 153  152  151  150  149  148  147  146  145  144  143  142  Older
DateSubjectAuthorDiscuss
15/10/2018
17:39
Hefty 80,000 buy near close.
1i1i1i
12/10/2018
11:13
The San Diego conference presentation will only highlight the huge potential and continued upwards momentum in this area and hence Tuffts and now commercial relationship having been signed over the last week.More to come .
hampton58
12/10/2018
00:07
As a Reach announcement it shouldn't have been shown as an RNS
bscuit
11/10/2018
18:58
Yep, you bought at the wrong time, happens to us all.
1i1i1i
11/10/2018
18:28
£1.20 - oh dear, I will not make much on these. Was buying at 80p + but wouldn't touch with a barge pole now. Were they not tipped to reach £2 a few months ago? Yours Disappointed
contact2fsnetcouk
11/10/2018
07:11
Avacta Group PLC Avacta's CTO to Present at Major US ConferenceSource: RNS Non-RegulatoryTIDMAVCTAvacta Group PLC11 October 201811 October 2018Avacta Group plc("Avacta" or "the Group" or "the Company")Avacta's Chief Technology Officer to Present at Major US ConferenceAvacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and reagents, is pleased to announce that its Chief Technology Officer, Dr Matt Johnson, will be presenting new data for Affimer research tools and diagnostics reagents at the Biomarkers and Precision Medicine Congress in San Diego on the 12 October 2018.Dr Johnson will be presenting recent data showing how the Affimer technology can be used to simplify diagnostics and other immunoassays.The data that Dr Johnson will present shows that immunoassays built using Affimers perform as well as, and in many cases better than, equivalent assays built using antibodies. These data are critical in driving the adoption of the new Affimer technology in a huge market that is dominated by antibodies.In the second part of his presentation, Dr Johnson will speak about an innovative class of Affimers that captures antibodies but only when the antibodies are bound to their own targets. This offers a route to improving an important type of diagnostic test to have a more specific and clearer result. The commercial potential for this class of Affimer is significant.- Ends -For further information from Avacta Group plc, please contact: Avacta Group plc Tel: +44 (0) 844 414 0452 Alastair Smith, Chief Executive Officer www.avacta.com Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: +44 (0) 207 220 0500 Geoff Nash / Giles Rolls - Nominated www.finncap.com Adviser Tim Redfern - Corporate Broking Tel: +44 (0) 203 705 9318 WG Partners Tel: +44 (0) 203 705 9217 Nigel Birks / Nigel Barnes www.wgpartners.co.uk David Wilson / Claes Spang Zyme Communications (Trade and Regional Tel: +44 (0)7787 502 947 Media) katie.odgaard@zymecommunications.com Katie Odgaard Yellow Jersey (Financial Media and Tel: +44 (0)7764 947137 IR) Tel: +44 (0)7946 424 651 Sarah Hollins avacta@yellowjerseypr.com Katie Bairsto About Avacta Group plc (www.avacta.com)Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDNRAFKKDKKBDBBKD(END) Dow Jones NewswiresOctober 11, 2018 02:00 ET (06:00 GMT)
1i1i1i
10/10/2018
19:37
More jam tomorrow stuff from Avacta. Once again no real disclosure on the deal detail but just enough to depress the share price!
lantanatony
10/10/2018
14:08
https://www.google.co.uk/amp/s/www.proactiveinvestors.co.uk/companies/amp/news/206741£1.20 target
1i1i1i
10/10/2018
08:51
With today's deal highlighting the upside potential there is on the Licensing side and off the validation of Tuffts Medical School, this brings the company into tier one going forward as this will only be the first of these deals.Come end of the month this stock will be trading at a substantial premium to current level.
hampton58
10/10/2018
08:27
Agree Spekky - common across aim.
the drewster
10/10/2018
08:23
There is a level of mistrust (of the board) here that is going to be hard to overcome.
spekky
10/10/2018
08:14
Under 25.5p to buy so some sells are actually buys. It's like getting blood out of a stone in this market atm I wonder what the price would do now if it issued the same news as it did when it went to 45p ish intraday on the last spike, struggle to get over 30p ??
dave4545
10/10/2018
08:10
It always surprises me the level of sells after a good announcement. Yes I know the mantra is buy the story, sell the news but it is hardly the case the price has gone up here ahead of the announcement. Aim is a casino......I guess you just have to play it to your advantage.
nobbygnome
10/10/2018
07:56
>> pug Fair summary I think....but nevertheless it looks undervalued to me.
nobbygnome
10/10/2018
07:56
Nice to see some positive news here.
dave4545
10/10/2018
07:51
Nobby & Timbo - You both here too - Lots of potential but still foggy ahead cashwise - but potentially (imo) worth the small nibble already taken.
pugugly
10/10/2018
07:43
25-27 pre market bodes well for the day....
nobbygnome
10/10/2018
07:39
PD-L1 Lag3 is massively interesting globally. Progress on that front will send the shares into the stratosphere. Meanwhile, deals like the one announced today increase the likelihood that no more funding rounds will further limit our ultimate profits!
the drewster
10/10/2018
07:11
Affimer technology is going to be revolutionary, this is just the beginning, exciting time to be here with such a tiny market cap.
1i1i1i
10/10/2018
07:08
So as the CEO intimated last week we have a licensing deal on the diagnostics side of the business. No revenues until next year at the earliest but it validates the usefulness of the products. I guess there will be more deals to follow....
nobbygnome
08/10/2018
15:11
Thanks Timbo
1i1i1i
08/10/2018
12:18
Slides and video from the recent TPI investor evening are here: https://www.youtube.com/watch?time_continue=1&v=zS3RF7xV1_c Good questions at the end 😉
timbo003
05/10/2018
08:25
I was at the Proactive investor meeting last night and was impressed by the presentation. I was already a shareholder as a result of the recent fund raising but hadn't really looked into the technology as much as I should have done. There are various aspects of the affimer platform which are advantageous. For example the fact that the structure gets around the antibody IP mean that this technology can be used in a variety of beneficial ways commercially. In addition the fact that the reagents used in the diagnostic area are plant based means it is distinctly separate from the therapeutic products. Plus the company is clearly focused on getting deals in the short term. The CEO said a diagnostics deal is imminent and others will follow. And the company is funded into 2020 and that doesn't include any deals in the interim. The key time will be when they get to the first in human studies which will be Q1 next year with the PDL1-LAGS bispecific. Yes I have bought some more this morning via spreadbet.... Nobby
nobbygnome
02/10/2018
14:28
Yep Academic CEO's don't you just love them!
lantanatony
02/10/2018
14:18
Unbelievable turnover more or less the same but losses have gone up to £8.83 million. This is over three times the turnover. How many more new share issues can they have?
poacher45
Chat Pages: 153  152  151  150  149  148  147  146  145  144  143  142  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V: D:20181022 21:54:32